Takeda’s TAK-003 dengue vaccine candidate succeeds in phase 3 efficacy trial
The first analysis of the tetravalent immunization against dengue efficacy study (TIDES) trial demonstrated that TAK-003 effectively prevented dengue fever caused by any of the four serotypes of